R
Ralph Winterhalder
Publications - 1
Citations - 984
Ralph Winterhalder is an academic researcher. The author has contributed to research in topics: Cetuximab & Pembrolizumab. The author has an hindex of 1, co-authored 1 publications receiving 578 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen,Denis Soulières,Christophe Le Tourneau,Christophe Le Tourneau,Christophe Le Tourneau,José Dinis,Lisa Licitra,Myung-Ju Ahn,Ainara Soria,Jean-Pascal Machiels,Jean-Pascal Machiels,Nicolas Mach,Ranee Mehra,Barbara Burtness,Pingye Zhang,Jonathan D. Cheng,Ramona F. Swaby,Kevin J. Harrington,Kevin J. Harrington,Mirelis Acosta-Rivera,Douglas Adkins,Morteza Aghmesheh,Mario Airoldi,Eduardas Aleknavicius,Yousuf Al-Farhat,Alain Algazi,Salah Almokadem,Anna Alyasova,Jessica Bauman,Marco Benasso,Alfonso Berrocal,Victoria Bray,Barbara Ann Burtness,F. Caponigro,Ana Castro,Terrence P. Cescon,Kelvin K. W. Chan,Arvind Chaudhry,Bruno Chauffert,Ezra W. Cohen,Tibor Csoszi,J. de Boer,Jean-Pierre Delord,Andreas Dietz,Charlotte Dupuis,Laurence Digue,Jozsef Erfan,Yolanda Alvarez,Mererid Evans,Mary J. Fidler,Martin David Forster,Signe Friesland,Apar Kishor Ganti,Lionnel Geoffrois,Cliona Grant,Viktor Gruenwald,Kevin J. Harrington,Thomas K. Hoffmann,Geza Horvai,Arturas Inciura,Raymond Woo-Jun Jang,Petra Jankowska,Antonio Jimeno,Mano Joseph,Alejandro Juarez Ramiro,Boguslawa Karaszewska,Andrzej Kawecki,Ulrich Keilholz,Ulrich Keller,Sung Bae Kim,Judit Kocsis,Nuria Kotecki,Mark F. Kozloff,Julio Lambea,Laszlo Landherr,Yuri Lantsukhay,Sergey Alexandrovich Lazarev,Lip Way Lee,Igor Dmitrievich Lifirenko,Danko Martincic,Oleg Vladmirovhich Matorin,Margaret McGrath,Krzysztof Misiukiewicz,John C. Morris,Fagim Fanisovich Mufazalov,Jiaxin Niu,Devraj Pamoorthy Srinivasan,Pedro Perez Segura,Daniel Rauch,Maria Leonor Ribeiro,Cristina P. Rodriguez,Frederic Rolland,Antonio Russo,Agnes Ruzsa,Frederico Sanches,Sang-Won Shin,Mikhail Shtiveland,Pol Specenier,Eva Szekanecz,Judit Szota,Carla M.L. van Herpen,Hector A. Velez-Cortes,William V. Walsh,Stefan Wilop,Ralph Winterhalder,Marek Z. Wojtukiewicz,Deborah Wong,Dan P. Zandberg +107 more
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.